Chest
Volume 103, Issue 4, April 1993, Pages 1190-1193
Journal home page for Chest

Clinical Investigations
Intrapleural Streptokinase as Adjunctive Treatment for Persistent Empyema in Pediatric Patients

https://doi.org/10.1378/chest.103.4.1190Get rights and content

Successful treatment of persistent empyema by intrapleural streptokinase is described in five pediatric patients. Their ages ranged from 18 months to 7 years. All experienced dramatic improvement in the resolution of their empyemas following intrapleural streptokinase. Improved chest tube drainage occurred concurrently with clinical improvement. Intrapleural instillation of streptokinase appears to be a safe adjunctive therapeutic tool to facilitate drainage of persistent empyema in the small number of pediatric patients in whom it has been employed. Additional study will be required to further assess the long-term therapeutic efficacy and consequences of intrapleural streptokinase therapy.

Section snippets

METHODS

Five consecutive cases of persistent empyema were retrospectively reviewed. All patients did not improve significantly with conventional therapy, including intravenous antibiotics and thoracostomy drainage and all were considered candidates for surgical decortication. Pleural fluid examination confirmed empyema in all patients.

Our protocol for the use of intrapleural streptokinase was as follows: pretreatment with analgesic and documentation of normal coagulation status. Instill 200,000 to

RESULTS

Table 1 summarizes clinical information on five pediatric empyema patients. Ages ranged from 18 months to 7 years. They experienced rapid improvement of their empyema following intrapleural streptokinase. Figure 1 depicts changes in chest tube drainage volume in relation to streptokinase infusion. Concurrently, all patients markedly improved clinically following streptokinase. Representative chest radiographs for case 5 are shown in Figure 2 (prestreptokinase), Figure 3 (after second

DISCUSSION

Streptokinase is a purified proteolytic enzyme produced from a bacterial protein of group C β-hemolytic streptococci. Streptokinase converts plasminogen to plasmin, an enzyme with proteolytic activity. Plasmin degrades fibrin clots as well as fibrinogen.6

The use of fibrinolytic enzymes to liquify fibrinous pleural exudates was first reported in 1949 by Tillett and Sherry.7 Sporadic case reports have followed the initial description, but these have rarely involved pediatric patients.8, 9, 10, 11

ACKNOWLEDGMENT:

The authors appreciate the editorial assistance of Natalie Purse.

REFERENCES (14)

There are more references available in the full text version of this article.

Cited by (0)

Manuscript received May 8, revision accepted August 5.

View full text